ClinicalTrials.gg
TerminatedNCT05288855VOCALUpdated Feb 10, 2026

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

A Phase 3 interventional study of Voclosporin and Placebo Oral Capsule in Adolescent Lupus Nephritis and Pediatric Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Terminated at 6 sites in 5 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
DSMB recommendation

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Lupus Nephritis with a site in Mexico — 3 open to participants now, 8 under way, 4 of them phase 3. Lupus Nephritis · Mexico.

Enrollment
31st of 32
9 · median 132
Started
2023
the only one that year
Phase 3
13 of 32
1 open now
Registered
27th of 32
by date
Lead sponsor
4 of 32
Aurinia Pharmaceuticals Inc.

Among the 32 studies in Lupus Nephritis with a site in Mexico, this one is the 31st largest by enrollment, is the only one that started in 2023, is one of 13 in phase 3, and was the 27th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

3 of the 32 studies in Lupus Nephritis with a site in Mexico are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Lupus Nephritis with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).

Read the detailed description

This is a 24 week, dose escalation study of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids, consisting of 3 treatment periods: Period 1 is double-blind, placebo controlled receiving 15.8 mg twice daily, Period 2 is open-label receiving 23.7 mg twice daily, Period 3 is open-label receiving 15.8 mg twice daily.

03

Conditions studied

  • Adolescent Lupus Nephritis
  • Pediatric Lupus Nephritis

Browse trials for

Keywords

  • Lupus nephritis
  • calcineurin inhibitors
  • voclosporin
  • adolescents
  • pediatrics
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Previous diagnosis of systemic lupus erythematosus (SLE) as per the 2019 EULAR/ ACR classification criteria.
  • Subjects with kidney confirmed active lupus nephritis.

Exclusion Criteria:

  • Estimated (eGFR) \<60 mL/minute/1.73 m2 at screening.
  • Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • drug or alcohol abuse prior to screening.
    • Malignant neoplasm.
    • Lymphoproliferative disease or previous total lymphoid irradiation.
    • Known severe viral infections within 3 months of screening; or known infection, or or C virus infection at any time prior to screening.
    • Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  • Other known clinically significant active medical conditions, for which the condition or the treatment of the condition may affect the study assessments or outcomes.
  • Currently taking or known need for any of the following medications:

    • biologic agents within 12 weeks prior to randomization, cyclophosphamide, calcineurin inhibitors (CNIs) and , initiation or dose change of ACE inhibitors/ARBs within 4 weeks prior to randomization, IV and IV immunoglobulin within 2 weeks prior to screening, strong /5 inhibitors and inducers within 2 weeks prior to randomization.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Voclosporin treatment group 1

    2 capsules (15.8 mg) BID of voclosporin

    Drug: Voclosporin

  • Placebo comparator
    Placebo treatment group 2

    2 capsules BID of placebo

    Drug: Placebo Oral Capsule

  • Experimental
    Voclosporin treatment group 3

    3 capsules (23.7 mg) BID of voclosporin

    Drug: Voclosporin

  • Experimental
    Voclosporin treatment group 4

    Maximum dose of 2 capsules (15.8 mg) BID of voclosporin.

    Drug: Voclosporin

Interventions

  • calcineurin inhibitor

  • DrugPlacebo Oral Capsule

    matching placebo capsule

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with renal response

    Renal response defined as UPCR ≤0.5 mg/mg, eGFR ≥60 mL/min/1.73 m2 or no decrease from baseline of \>20%, no rescue medication and no steroid use \>10 mg/day for ≥3 consecutive days or for ≥7 days in total between week 16 to 24

    Time frame: Week 24

Secondary outcomes

  1. Time to UPCR of ≤0.5 mg/mg.

    Time in days to reduction in UPCR to ≤ 0.5 mg/mg

    Time frame: Baseline to Week 24

  2. Proportion of subjects with partial renal response

    defined as ≥50% reduction from baseline in UPCR

    Time frame: Week 24

  3. Time to 50% Reduction in UPCR

    Time in days to reduction from baseline UPCR of at least 50% Organ Class, and preferred term.

    Time frame: Baseline to Week 24

  4. Number of treatment-emergent adverse events (TEAEs) will be summarized by treatment group

    Treatment-emergent adverse events will be summarized by treatment group, System Organ Class, and preferred term

    Time frame: Baseline to Week 24

07

Study locations

6 sites
  • Nemours Children's Hospital, Orlando
    Orlando, Florida 13535, United States
  • Clinica de la Costa S.A.S
    Barranquilla, Atlántico 76100, Colombia
  • Yokohama City University Hospital
    Yokohama, Kanagawa, Japan
  • Centro de Especialidades Medicas del Sureste
    Mérida, Yucatán 97000, Mexico
  • Hospital Infantil de México Federico Gómez
    Mexico City, Mexico
  • Siriraj Hospital
    Bangkok, 10700, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jul 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2022
First posted
Mar 21, 2022
StartActual
Oct 10, 2023
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 3, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05288855
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Oct 10, 2023
Primary completion
Jul 3, 2025
Completion
Jul 3, 2025
Last update
Feb 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion